Objective To evaluate the short -term effect of tegafur combined with oxaliplatin in the treatment of advanced colorectal cancer and its impact on long -term prognosis .Methods 70 patients with advanced colorectal cancer were selected .The patients were randomly divided into tegafur group ( oxaliplatin plus tegafur ) and capecitabine group ( oxaliplatin combined with capecitabine ) according to the digital table ,35 cases in each group , The short-term efficacy,side effects,2-year survival rate and median survival time were compared between the two groups.Results The total effective rate of the tegafur group was 85.71％, which of the capecitabine group was 77.14％,but the difference was not statistically significant between the two groups (χ2 =0.850,P=0.356).After treatment,the levels of VEGF in the two groups were significantly lower than those before treatment ( t =21.694, 20.558,P=0.305,0.249).There was no statistically significant difference between the two groups (t =0.998, 1.242,P=0.281,0.307).The 1-year survival rate was 51.43％and the 2-year survival rate was 25.71％of the tegafur group,compared with 45.71％ and 17.14％ in the capecitabine group ,the differences were not statistically significant (χ2 =0.229,0.764,P=0.632,0.382).The median survival time of the tegafur group was 13.5 months, which of the capecitabine group was 13.0 months,there was no statistically significant difference ( Z=1.304,P=0.752).The incidence rate of hand -foot syndrome of the tegafur group was 5.71％,which was lower than 22.86％of the capecitabine group (χ2 =4.163,P=0.027).Conclusion The efficacy of tegafur combined with oxaliplatin in the treatment of advanced colorectal cancer is similar to capecitabine plus oxaliplatin , with a slightly lower complication rate.

Objective To investigate the difference on long-term effect of laparoscopy and laparotomy operation in patients with colon cancer. Methods Medical records of 150 patient who nderwent radical operation of colon cancer by the same team of surgeons in our hospital from January, 2010 to January, 2013 were randomly selected and reviewed retrospectively. Patients were divided into laparoscopy operation group (77 patients) and laparotomy operation group (73 patients) according to the type of operation. Rates of 2-year and 5-year survival, the incidence of local recurrence and distant metastasis as well as the incidence of complications during follow-up period (6 months to 5 years). Results Rates, of 2-year and 5-year survival in laparoscopy operation group were 79. 22％ and 31. 17％ respectively. Rates of 2-year and 5 -year survival in laparotomy operation group were 79. 45％ and 30. 14％ respectively. There were no statistical differences between two groups (P＞0. 05). The incidence of recurrence and metastasis in laparoscopy operation group was 20. 78％, which was not statistically different from that in laparotomy operation group (17. 81％) (P＞0. 05). The incidence of complications during follow-up period in laparoscopy operation group was 5. 19％, which was statistically different from that in laparotomy operation group(17. 81％)(P＜0. 05). Conclusion There was no significant difference between laparoscopy and laparotomy operation in patients with colon cancer. However, there were fewer complications after laparoscopy oper- ation. Laparoscopy operation enjoyed advantages over laparotomy operation and it was worth further study and promotion.

The widespread of tigecycline resistance gene tet(X4) has a serious impact on the clinical efficacy of tigecycline. The development of effective antibiotic adjuvants to combat the looming tigecycline resistance is needed. The synergistic activity between the natural compound β-thujaplicin and tigecycline in vitro was determined by the checkerboard broth microdilution assay and time-dependent killing curve. The mechanism underlining the synergistic effect between β-thujaplicin and tigecycline against tet(X4)-positive Escherichia coli was investigated by determining cell membrane permeability, bacterial intracellular reactive oxygen species (ROS) content, iron content, and tigecycline content. β-thujaplicin exhibited potentiation effect on tigecycline against tet(X4)-positive E. coli in vitro, and presented no significant hemolysis and cytotoxicity within the range of antibacterial concentrations. Mechanistic studies demonstrated that β-thujaplicin significantly increased the permeability of bacterial cell membranes, chelated bacterial intracellular iron, disrupted the iron homeostasis and significantly increased intracellular ROS level. The synergistic effect of β-thujaplicin and tigecycline was identified to be related to interfere with bacterial iron metabolism and facilitate bacterial cell membrane permeability. Our studies provided theoretical and practical data for the application of combined β-thujaplicin with tigecycline in the treatment of tet(X4)-positive E. coli infection.
Humans ; Tigecycline/pharmacology* ; Escherichia coli/metabolism* ; Reactive Oxygen Species/therapeutic use* ; Plasmids ; Anti-Bacterial Agents/metabolism* ; Escherichia coli Infections/microbiology* ; Bacteria/genetics* ; Microbial Sensitivity Tests